Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Rest of World
Net revenue	$ 72,810	$ 61,931
U.S.
Rest of World
Net revenue	65,765	55,391
Rest of World
Rest of World
Net revenue	7,045	6,540
Total Drug Products
Rest of World
Net revenue	1,159	1,076
Total Drug Products | U.S.
Rest of World
Net revenue	561	835
Total Drug Products | Rest of World
Rest of World
Net revenue	598	241
Total Concentrate Products
Rest of World
Net revenue	71,651	60,855
Total Concentrate Products | U.S.
Rest of World
Net revenue	65,204	54,556
Total Concentrate Products | Rest of World
Rest of World
Net revenue	6,447	6,299
Product Sales - Point-in-time | Drug Product Sales
Rest of World
Net revenue	903	835
Product Sales - Point-in-time | Drug Product Sales | U.S.
Rest of World
Net revenue	561	835
Product Sales - Point-in-time | Drug Product Sales | Rest of World
Rest of World
Net revenue	342	0
Product Sales - Point-in-time | Concentrate Product Sales
Rest of World
Net revenue	69,162	58,913
Product Sales - Point-in-time | Concentrate Product Sales | U.S.
Rest of World
Net revenue	62,715	52,614
Product Sales - Point-in-time | Concentrate Product Sales | Rest of World
Rest of World
Net revenue	6,447	6,299
Product Sales - Point-in-time | Concentrate Product License Fee
Rest of World
Net revenue	2,489	1,942
Product Sales - Point-in-time | Concentrate Product License Fee | U.S.
Rest of World
Net revenue	2,489	1,942
Product Sales - Point-in-time | Concentrate Product License Fee | Rest of World
Rest of World
Net revenue	0	0
License Fee – Over time | Drug License Fee
Rest of World
Net revenue	256	241
License Fee – Over time | Drug License Fee | U.S.
Rest of World
Net revenue	0	0
License Fee – Over time | Drug License Fee | Rest of World
Rest of World
Net revenue	$ 256	$ 241